HIF-Mediated Detrimental Consequences of Chronic Intermittent Hypoxia
HIF-Mediated Detrimental Consequences of Chronic Intermittent Hypoxia
批准号:
9243108
负责人:
JOSEF T PRCHAL
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-01-01 至 2020-12-31
关键词:
AdultAffectApneaAttenuatedB-LymphocytesBNIP3L geneBloodBlood CellsBlood PlateletsBlood PressureBlood VesselsBreathingCarbon MonoxideCarotid BodyCellsChicagoChronicClinicalCollaborationsContinuous Positive Airway PressureCystathionineDataDiabetes MellitusDiffuseDiseaseDown-RegulationEmergency department visitEpidemicErythrocytesErythroidErythropoiesisErythropoietinExcisionExhalationFrequenciesFunctional disorderGenerationsGenesGlucose IntoleranceGoalsHealthHealthcare SystemsHematocrit procedureHemolysisHormonesHospitalizationHydrogen SulfideHypertensionHypoxemiaHypoxiaHypoxia Inducible FactorImpaired cognitionInflammationLeadLinkLungLyaseMalignant NeoplasmsMeasuresMediatingMedicalMedicineMemoryMessenger RNAMetabolicMicroRNAsMitochondriaModelingMolecularMononuclearMorbidity - disease rateMyocardial InfarctionObesityObstructive Sleep ApneaOxygenPathway interactionsPatientsPeriodicityPersonsPharmacologyPlasmaPlayPolycythemiaPopulationProcessProductionProspective StudiesPulmonary Heart DiseasePulmonologyReactive Oxygen SpeciesRecurrenceReflex actionReflex controlRegulationResearchResearch ProposalsReticulocytesRoleSecondary toSeveritiesSleepSleep Apnea SyndromesT-LymphocyteTestingTissuesTranscriptUniversitiesUp-RegulationUtahVeteransVisitbHLH-PAS factor HLFbody sensecatalasecatalase-polyethylene glycolcostdesignfallsgranulocyteheme oxygenase-2hypoxia inducible factor 1indexinginsightmetabolomemonocytemouse modelneurotransmissionnovelpreventprofessorprogenitorpyruvate kinase deficiencysensortranscription factorurgent care
中文摘要
阻塞性睡眠呼吸暂停(OSA)是指睡眠中呼吸受阻或受阻的时期,
英文摘要
Obstructive sleep apnea (OSA), a term for periods during sleep when breathing is blocked or impeded,
is a highly prevalent medical condition, increases with obesity and diabetes, and affects 9-18% of the adult
U.S. population. OSA occurs because of recurrent upper airway collapse during sleep leading to reductions in
airflow with cyclic changes in body oxygen, and results in a state of chronic intermittent hypoxia. Many
essential processes, such as production of red blood cells, energy regulation, and formation of new blood
vessels, are regulated by hypoxia. OSA is an exceedingly common problem that has been linked to high blood
pressure, diabetes, poor memory and heart attacks. Hypoxia leads to up-regulation of hypoxia-inducible factors
(HIFs). HIF-1 and HIF-2 were discovered as a result of studies of erythropoietin (EPO), the key hormone that
stimulates erythroid progenitors and regulates the production of erythrocytes, the subject of the PI's previous
VA support.
This application is designed to gain novel insights into the contribution of HIFs, which regulate
erythropoiesis, to the pathophysiology of OSA. The PI of this proposal has been intrigued that, in contrast to
other hypoxic conditions, his major clinical/academic focus of polycythemia/erythrocytosis is not a common
feature of OSA. During prolonged hypoxia, HIFs mediate an increase in erythropoiesis, leading to an increased
red blood cell (RBC) mass. Upon return to normoxia, the increased RBC mass is abruptly overcorrected by
the preferential destruction, i.e., hemolysis, of hypoxia-formed young RBCs, a phenomenon termed
neocytolysis. We created a novel mouse model of neocytolysis and used this model to show that neocytolysis
is mediated by excessive accumulation of reactive oxygen species (ROS), increased mitochondria in RBCs,
and increased micro RNA miR-21 which down-regulates catalase.
We also obtained preliminary data suggesting that neocytolysis is the main mechanism preventing
polycythemia in patients with OSA. We observed that erythrocytes and reticulocytes of OSA patients have
reduced catalase transcripts and activity, along with increased miR-21, and that these levels normalize with
CPAP treatment. We also observed that in uncorrected OSA, increased mitochondrial mass and levels of ROS
are found not only in reticulocytes and mature RBCs, but also in other blood cells such as platelets, T-cells, B-
cells, granulocytes, and mononuclear cells. With CPAP treatment, mitochondrial ROS decrease and
mitochondrial mass normalizes.
To accomplish our research goals outlined in this research proposal, we will elucidate OSA changes in
HIF-regulated pathways using peripheral blood cells to confirm our preliminary findings that neocytolysis
occurs secondary to chronic intermittent hypoxia in most OSA patients. We will determine the metabolic
consequences of chronic intermittent versus sustained hypoxia in a mouse model of neocytolysis and assess
the effect(s) of pharmacological manipulation of HIFs. We will evaluate the effects of carbon monoxide (CO),
which is increased by hemolysis, on the activity of the carotid body (CB). The CB is the key sensor of arterial
blood oxygen. Hypoxia increases neural signals from the CB which, through chemosensory reflexes, controls
breathing and blood pressure, a principal adaptation to hypoxia. Enhanced CB chemosensory reflexes play a
substantial role in OSA pathophysiology. Emerging evidence suggests that hypoxic sensing by the CB
involves blood oxygen-dependent interplay between CO generation by heme oxygenase-2 and hydrogen
sulfide synthesis by cystathionine-ϒ-lyase. We will evaluate, using an exhaled CO end-tidal breath analyzer,
whether increased CO produced by hemolyzed RBC in OSA influences CB sensing and ensuing chemosensory
reflexes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanism of thrombosis in two myeloproliferative neoplasms (MPNs), polycythemia vera and essential thrombocythemia
-
批准号:10699552
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2023
-
负责人:JOSEF T PRCHAL
-
依托单位:
HIF-Mediated Detrimental Consequences of Chronic Intermittent Hypoxia
-
批准号:10237109
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2017
-
负责人:JOSEF T PRCHAL
-
依托单位:
Erythropoietin in Non-Erythroid Cells: Function and Regulation
-
批准号:7796916
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:JOSEF T PRCHAL
-
依托单位:
Erythropoietin in Non-Erythroid Cells: Function and Regulation
-
批准号:7910501
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:JOSEF T PRCHAL
-
依托单位:
Erythropoietin in Non-Erythroid Cells: Function and Regulation
-
批准号:8391135
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:JOSEF T PRCHAL
-
依托单位:
Erythropoietin in Non-Erythroid Cells: Function and Regulation
-
批准号:8195889
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:JOSEF T PRCHAL
-
依托单位:
Genetic Basis of Polycythemia Vera
-
批准号:7502148
-
项目类别:
-
资助金额:$34.88万
-
财政年份:2007
-
负责人:JOSEF T PRCHAL
-
依托单位:
Genetic Basis of Polycythemia Vera
-
批准号:8064158
-
项目类别:
-
资助金额:$46.32万
-
财政年份:2006
-
负责人:JOSEF T PRCHAL
-
依托单位:
Genetic Basis of Polycythemia Vera
-
批准号:7113537
-
项目类别:
-
资助金额:$28.93万
-
财政年份:2005
-
负责人:JOSEF T PRCHAL
-
依托单位:
CORE--DIAGNOSTIC LABORATORY
-
批准号:6584656
-
项目类别:
-
资助金额:$22.86万
-
财政年份:2002
-
负责人:JOSEF T PRCHAL
-
依托单位:
STEM CELL KINETICS AND GENETIC THERAPIES FOR SICKLE CELL DISEASE
-
批准号:6584659
-
项目类别:
-
资助金额:$22.86万
-
财政年份:2002
-
负责人:JOSEF T PRCHAL
-
依托单位:
Hematology Training Grant
-
批准号:6666737
-
项目类别:
-
资助金额:$30.58万
-
财政年份:2002
-
负责人:JOSEF T PRCHAL
-
依托单位:
Hematology Training Grant
-
批准号:6409810
-
项目类别:
-
资助金额:$22.77万
-
财政年份:2002
-
负责人:JOSEF T PRCHAL
-
依托单位:
CORE--DIAGNOSTIC LABORATORY
-
批准号:6669241
-
项目类别:
-
资助金额:$22.86万
-
财政年份:2002
-
负责人:JOSEF T PRCHAL
-
依托单位:
Hematology Training Grant
-
批准号:6791244
-
项目类别:
-
资助金额:$38.51万
-
财政年份:2002
-
负责人:JOSEF T PRCHAL
-
依托单位:
STEM CELL KINETICS AND GENETIC THERAPIES FOR SICKLE CELL DISEASE
-
批准号:6669244
-
项目类别:
-
资助金额:$22.86万
-
财政年份:2002
-
负责人:JOSEF T PRCHAL
-
依托单位:
STEM CELL KINETICS AND GENETIC THERAPIES FOR SICKLE CELL DISEASE
-
批准号:6456249
-
项目类别:
-
资助金额:$22.86万
-
财政年份:2001
-
负责人:JOSEF T PRCHAL
-
依托单位:
CORE--DIAGNOSTIC LABORATORY
-
批准号:6456246
-
项目类别:
-
资助金额:$22.86万
-
财政年份:2001
-
负责人:JOSEF T PRCHAL
-
依托单位:
CORE--DIAGNOSTIC LABORATORY
-
批准号:6325967
-
项目类别:
-
资助金额:$16.27万
-
财政年份:2000
-
负责人:JOSEF T PRCHAL
-
依托单位:
HYPOXIA SENSING IN CHUVASH POLYCYTHEMIA
-
批准号:6527700
-
项目类别:
-
资助金额:$26.16万
-
财政年份:2000
-
负责人:JOSEF T PRCHAL
-
依托单位:
海外基金